In comparison, we have examined the in vivo effects of Cpd1 treatment on small intestine and gut-resident ILC populations as it relates to clinical outcomes in the EAE model in a manner complementary to the study of Prada and colleagues in defining how Ffar2 agonism effectively modulates CNS autoimmunity. Here, FFAR2 is linked to Autoimmunity.